mglu4

L-APB is an effective and specific agonist for the group III mGluRs (EC50s: 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6, and mGlu7 receptors, respectively).

Valiglurax (VU2957)，也称为 VU0652957和 VU2957，是一种强效、选择性、中枢神经系统渗透剂，可口服生物利用的 mGlu4正变构调节剂。VU2957具有良好的跨物种的体内外药理学和药代动力学性质。VU2957被评估为治疗帕金森病的临床前开发候选药物。

Foliglurax monohydrochloride Antiparkinsonian effect. is a highly selective and potent, brain-penetrant metabotropic glutamate receptor 4 positive allosteric modulator (mGluR4 PAM) , with an EC50 of 79 nM.

VU6001376 is an effective and selective positive allosteric modulator of the metabotropic glutamate receptor 4 (EC50: 50.1 nM).

mGlu4 receptor agonist 1 (compound 62) is a highly effective positive allosteric modulator of mGlu4 receptors, displaying an EC 50 of 308 nM. Additionally, it exhibits noteworthy anxiolytic and antipsychotic properties [1].

Foliglurax is a highly selective brain-penetrant metabotropic glutamate receptor 4 positive allosteric modulator (mGluR4 PAM) (EC50: 79 nM).

VU0364770 (VU 0364770) 是一种选择性mGlu4正变构调节剂，对 mGlu5 具有拮抗活性，对 mGlu6 具有正变构调节活性。它还对 MAO 具有活性，对人 MAO-A 和 MAO-B 的 Ki 值分别为8.5 和 0.72 μM。

VU0483605 是一种有效的特异性 mGluR1 正变构调节剂，对人和大鼠的 EC50 分别为 390 和 356 nM。

TCN238 是一种可口服的代谢型谷氨酸受体 4 正变构调节剂，EC50值为 1 μM。

VU0361737 (ML-128) 是一种高效选择性的，中枢神经系统渗透性的代谢型谷氨酸受体 4(mGluR4)正变构调节剂，对人类和大鼠 mGluR4作用的EC50值分别为 240 和 110 nM。它具有神经保护作用，有用于帕金森氏病的研究潜力。

DCG-IV is an effective agonist of class II mGluR. DCG-IV has anticonvulsant and neuroprotective effects. The EC50 of mGlu2R and mGlu3R are 0.35 and 0.09 μM, respectively. DCG-IV is also a competitive antagonist of Group I (IC50: mGlu1 / 5R = 389/630 μM) a

VU0364770 hydrochloride is a potent and selective mGlu4 positive allosteric modulator (PAM) (EC50s: 290 nM and 1.1 μM at rat mGlu4 and human mGlu4 receptor, respectively).

mGlu4 receptor agonist

TC-N 22A 是一种作用力强的、可选择的、口服具有活性的、可以通过血脑屏障的 mGlu4 正向别构调节剂 (PAM)。TC-N 22A 在表达人 mGlu4 的 BHK 细胞中 EC50 表现为 9 nM。TC-N 22A 在激动和正向别构模型中对 mGlu 1、2、3、5 和 7 受体的活性表现很低 (EC50 >10 μM)。TC-N 22A 可以用于中枢神经系统疾病的研究。

VU0415374 is a positive allosteric modulator of mGlu4.

FP0429 is an agonist of mGlu4.

LSP1-2111 is a mGlu4 receptor subtype agonist.

LSP4-2022, a mGlu4 selective agonist, increases behavioral despair in mouse models of antidepressant action.

VU0080241 is a positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4).

VU0418506 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGlu4).

VU0477886 is a potent mGlu4 positive allosteric modulator (PAM) with robust efficacy in a standard preclinical Parkinson's disease model, haloperidol-induced catalepsy (HIC).

Lu AF21934 是一种脑渗透性和选择性 mGlu4 受体阳性变构调节剂，对人mGlu4的IC50为500 nM。

VU0155041 是一种选择性的mGluR4正变构调节剂，有用于帕金森病的研究潜力，对人和大鼠 mGluR4 的EC50值分别为 798 和 693 nM。

L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively[1][2]. L-AP4 (5-30 μg, intrathecal inhection 4-5 days) significantly increases the paw withdrawal threshold in response to application of von Frey filaments in eight nerve-ligated rats in a dose-dependent manner. Intrathecal administration of different doses of L-AP4 is not associated with any evident motor dysfunction[2].Intrathecal injection of 30 μg of L-AP4 does not significantly alter the paw withdrawal latency in these normal rats[2].Topical application of 5 to 50 μM L-AP4 to the spinal cord significantly inhibited the evoked response of neurons to touch, pressure, pinch, and von Frey filaments in a concentration-dependent fashion[2]. Animal Model: Rats.[2] [1]. Selvam C, et al. Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites. J Med Chem. 2018 Mar 8;61(5):1969-1989. [2]. Chen SR, et al. Distinct roles of group III metabotropic glutamate receptors in control of nociception and dorsal horn neurons in normal and nerve-injured Rats. J Pharmacol Exp Ther. 2005 Jan;312(1):120-6.